


Fig. 1




Fig. 2





Fig. 3

Fig. 4

(A) **24H5 (182-D758-034)**



(B) **85A3 (182-D756-002)**





Fig. 4C


45C1
182-D1106-187


125E1
182-D1106-279

163E12
182-D1106-294

HEK293-
huCLD18A2








166E2
182-D1106-308

175D10
182-D1106-362

HEK293-
huCLD18A2






Fig. 5







	HEK293-CLD18A2	HEK293-CLD18A2-X2-Myc	HEK293-CLD18A2-X1-HA	
(A)				24H5 (182-D758-034)
(B)				9E8 (182-D758-011)

Fig. 5







	HEK293-CLD18A2	HEK293-CLD18A2-X2-Myc	HEK293-CLD18A2-X1-HA	
(C)				26B5 (182-D758-035)
(D)				19B9 (182-D758-024)

Fig. 6A






	HEK293-CLD18A2	HEK293-CLD18A1
43A11 182-D1106-062		
37H8 182-D1106-056		

Fig. 6B


45C1
182-D1106-187
163E12
182-D1106-294
HEK293-huCLD18A1
HEK293-huCLD18A2
Sample_109-Well_001
Sample_103-Well_001
Sample_013-Well_001
Sample_007-Well_001
GC 182red Red-A
PI Yellow-A
Q1
Q2
Q3
Q4




Fig. 7




Fig. 7




Fig. 8






Fig. 8

Fig. 9


600 bp
500 bp
400 bp
DAN-G
NTC
KATO-III


600 bp
500 bp
400 bp
100 bp
Marker
NTC
LnCap
PC-3
SNU-16
DAN-G




Fig. 10




Fig. 11




Fig. 12A

Fig. 12B



45C1
182-D758-187
125E1
182-D1106-279
163E12
182-D1106-294
KATO-III
166E2
182-D1106-308
175D10
182-D1106-362
KATO-III


Fig. 13


NUGC-4

KATO-III

163E12

182-D1106-294





61C2

182-D1106-67-D1




Fig. 14



1 50
NP_062789 (1) -------MATTTCQVVGLLLSLLGLAGCIAATGMDMWSTQDLYDNPVTAV
NP_057453 (1) -------MSTTTCQVVAFLLSILGLAGCIAATGMDMWSTQDLYDNPVTSV
AAL15636 (1) -------MSVTACQGLGFVVSLIGFAGIIAATCMDQWSTQDLYNNPVTAV
NP_001002026 (1) -------MAVTACQGLGFVVSLIGIAGIIAATCMDQWSTQDLYNNPVTAV
Extrazellular
1
51 100
NP_062789 (44) FQYEGLWRSCVQQSSGFTECRPYFTILGLPAMLQAVRALMIVGIVLGVIG
NP_057453 (44) FQYEGLWRSCVRQSSGFTECRPYFTILGLPAMLQAVRALMIVGIVLGAIG
AAL15636 (44) FNYQGLWRSCVRESSGFTECRGYFTLLGLPAMLQAVRALMIVGIVLGVIG
NP_001002026 (44) FNYQGLWRSCVRESSGFTECRGYFTLLGLPAMLQAVRALMIVGIVLGAIG
Extrazellular 1
101 150
NP_062789 (94) ILVSIFALKCIRIGSMDDSAKAKMTLTSGILFIISGICAIIGVSVFANML
NP_057453 (94) LLVSIFALKCIRIGSMEDSAKANMTLTSGIMFIVSGLCAIAGVSVFANML
AAL15636 (94) ILVSIFALKCIRIGSMDDSAKAKMTLTSGILFIISGICAIIGVSVFANML
NP_001002026 (94) LLVSIFALKCIRIGSMEDSAKANMTLTSGIMFIVSGLCAIAGVSVFANML
Extra / intra 3 N-Glyc
ex2
151 200
NP_062789 (144) VTNFWMSTANMYSGMGGMGGMVQTVQTRYTFGAALFVGWVAGGLTLIGGV
NP_057453 (144) VTNFWMSTANMYTGMG---GMVQTVQTRYTFGAALFVGWVAGGLTLIGGV
AAL15636 (144) VTNFWMSTANMYSGMGGMGGMVQTVQTRYTFGAALFVGWVAGGLTLIGGV
NP_001002026 (144) VTNFWMSTANMYTGMG---GMVQTVQTRYTFGAALFVGWVAGGLTLIGGV
Extrazellular 2
201 250
NP_062789 (194) MMCIACRGLTPDDSNFKAVSYHASGQNVAYRPGGFKASTGFGSNTRNKKI
NP_057453 (191) MMCIACRGLAPEETNYKAVSYHASGHSVAYKPGGFKASTGFGSNTKNKKI
AAL15636 (194) MMCIACRGLTPDDSNFKAVSYHASGQNVAYRPGGFKASTGFGSNTRNKKI
001002026 (191) MMCIACRGLAPEETNYKAVSYHASGHSVAYKPGGFKASTGFGSNTKNKKI
251 271
NP_062789 (244) YDGGARTEDDEQSHPTKYDYV
NP_057453 (241) YDGGARTEDEVQSYPSKHDYV
AAL15636 (244) YDGGARTEDDEQSHPTKYDYV
NP_001002026 (241) YDGGARTEDEVQSYPSKHDYV

Fig. 15A



38G5
182-D1106-057-D1
38H3
182-D1106-058-D1
HEK293-muCLD18A1
HEK293-muCLD18A2
Sample_008-Well_001
Sample_009-Well_001
Sample_032-Well_001
Sample_033-Well_001
Alexa-647 Red-A
Yellow-A
Q1
Q2
Q3
Q4

Fig. 15B



37G11
182-D1106-055-D1
45C1
182-D1106-187
163E12
182-D1106-294
HEK293-muCLD18A1
HEK293-muCLD18A2
Sample_006-Well_001
Sample_033-Well_001
Sample_056-Well_001
Sample_030-Well_001
Alexa-647 Red-A
Red-A
Yellow-A
Q1
Q2
Q3
Q4

Fig. 16

(A)






Fig. 16

(B)






(C)


Fig. 16

Fig. 17


(A)




Stomach



Kidney




Breast



Lung alveoli

Fig. 17

Stomach carcinomas



(B)

Lung carcinomas





Fig. 18A

Fig. 18B








Fig. 18C

Fig. 18D



Hek293-mock



Hek293-GC182A2




Fig. 18E



HEK293-CLD18A2
% dead cells
0
5
10
15
20
25
30
35
40
45
85A3
28D10
24H5
26D12
antibody

Fig. 19

Fig. 20




CHO-CLD18A2
CHO-CLD18A1
% specific lysis
60,0
50,0
40,0
30,0
20,0
10,0
0,0
-10,0
antibody
24H5
26D12
28D10
37G1
37H8
38G5
38H3
39F1
4IC6
42E12
43A1
44E10
47D12
6IC2

Fig. 21

(A)


182-D756-001/75B8
CHO-CLD18A2
% specific lysis
0
10
20
30
40
50
60
100
30
10
3
1
antibody concentration (µg/ml)

(B)



182-D758-040/28D10
CHO-CLD18A2
% specific lysis
0
20
40
60
10
1
0,1
antibody concentration (µg/ml)

Fig. 21

(C)



182-D1106-056/37H8
CHO-CLD18A2
% specific lysis
0
10
20
30
40
50
60
10
3,3
1
antibody concentration (µg/ml)

Fig. 22



HEK293-CLD18A2
% specific killing
100
80
60
40
20
0
26B5
182-D758-035
37H8
182-D1106-056
38G5
182-D1106-057
47D12
182-D1106-064
61C2
182-D1106-067
antibody

Fig. 23



HEK293-CLD18A1
% specific killing
100
80
60
40
20
0
26B5
182-D758-035
37H8
182-D1106-056
38G5
182-D1106-057
47D12
182-D1106-064
61C2
182-D1106-067
antibody

Fig. 24



Tumor growth inhibition - HEK293-CLD18A2 (mean)
Tumor volume in mm 3
3000
2500
2000
1500
1000
500
0
0
5
10
15
20
25
30
35
Time after tumor inoculation in days
37G11 (182-D1106-055)
42E12 (182-D1106-061)
43A11 (182-D1106-062)
untreated (PBS)

Fig. 25A




Kaplan-Meier survival plot
Survival in %
100
80
60
40
20
0
0
10
20
30
40
50
60
70
80
90
100
110
120
130
Time after tumor inoculation in days
untreated (PBS)
37G11 (182-D1106-055)
42E12 (182-D1106-061)
43A11 (182-D1106-062)

Fig. 25B


Kaplan-Meier survival plot
Survival in %
Time after tumor inoculation in days
0
20
40
60
80
100
0
10
20
30
40
50
60
70
80
untreated (PBS)
43A11 (182-D1106-062)
45C1 (182-D758-187)
125E1 (182-D1106-279)
163E12 (182-D1106-294)
166E2 (182-D1106-308)
175D10 (182-D1106-362)




Kaplan-Meier survival plot
untreated (PBS)
43A11 (182-D1106-062)
163E12 (182-D1106-294)
175D10 (182-D1106-362)
Therapy Start
Survival in %
Time after tumor inoculation in days
0
20
40
60
80
100
0
10
20
30
40
50
60

Fig. 26

Fig. 27A


Tumor growth inhibition - DAN-G (mean)
37G11 (182-D1106-055)
42E12 (182-D1106-061)
43A11 (182-D1106-062)
PBS
tumor volume (mm³)
400
300
200
100
0
0
5
10
15
20
25
30
days



Kaplan-Meier survival plot
untreated (PBS)
43A11 (182-D1106-062)
45C1 (182-D758-187)
125E1 (182-D1106-279)
163E12 (182-D1106-294)
166E2 (182-D1106-308)
175D10 (182-D1106-362)
Survival in %
100
80
60
40
20
0
0
10
20
30
40
50
60
70
80
Time after tumor inoculation in days

Fig. 27B




Fig. 28




Fig. 29




Fig. 30

Fig. 31A



ch-43A11 (ch-182-D1106-062)
ch-125E1 (ch-182-D1106-279)
ch-163E12 (ch-182-D1106-294)
HEK293-huCLD18A1
HEK293-huCLD18A2
KATO-III
Sample_123-Well_001
Sample_142-Well_001
Sample_135-Well_001
Sample_027-Well_001
Sample_046-Well_001
Sample_039-Well_001
GC-182 Red-A
PI Yellow-A
Q1
Q2
Q3
Q4

Fig. 31B



ch-166E2 (ch-182-D1106-308)
ch-175D10 (ch-182-D1106-362)
HEK293-huCLD18A1
HEK293-huCLD18A2
KATO-III
Sample_164-Well_001
Sample_175-Well_001
Sample_068-Well_001
Sample_079-Well_001
Sample_068-Well_001
Sample_079-Well_001
GC-182 Red-A
GC182 Red-A
PI Yellow-A
Q1
Q2
Q3
Q4

Fig. 32




CHO-CLD18A2
% specific lysis
0
10
20
30
40
50
60
70
80
ch-163E12
ch-182-D1106-294
ch-166E2
ch-182-D1106-308
ch-175D10
ch-182-D1106-362
antibodies

Fig. 33


KATO-III, 6h
% specific killing
0
5
10
15
20
25
ch-163E12
ch-182-D1106-294
ch-175D10
ch-182-D1106-362
antibodies